Liver Diseases: all 2,094 studies

Page 5 of 21. Open to participants first (390), then studies with results posted, then the rest; newest registration first within each.

• Study of NST-6179 in Healthy SubjectsCompletedNCT05181085Phase 1Results posted
• Biobehavioral Pathways Underlying Alcohol Use and HealthCompletedNCT05135767Not applicableResults posted
• A Study to Evaluate Liver Stiffness With Shear Wave ElastographyCompletedNCT05097963Not applicableResults posted
• Digoxin In Treatment of Alcohol Associated HepatitisTerminatedNCT05014087Phase 2Results posted
• The University of Michigan Wellness for Liver Health StudyCompletedNCT05010070Phase 1/2Results posted
• Study to Estimate the Effects of Hepatic Impairment on the Pharmacokinetics (PK) of PF-07321332CompletedNCT05005312Phase 1Results posted
• A Study of Belzutifan (MK-6482) in Participants With Hepatic Impairment (MK-6482-020)CompletedNCT04995484Phase 1Results posted
• A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)CompletedNCT04944992Phase 2Results posted
• Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)CompletedNCT04929483Phase 2Results posted
• Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)CompletedNCT04906421Phase 2Results posted
• Pharmacokinetics of Sotorasib in Healthy Participants and Participants With Moderate or Severe Hepatic ImpairmentCompletedNCT04887064Phase 1Results posted
• Study in Healthy Adults Evaluating PF-07202954CompletedNCT04857437Phase 1Results posted
• Noninvasive Biomarkers of Metabolic Liver Disease 1.1CompletedNCT04828551Not applicableResults posted
• Pediatric Liver Fat Quantification (LFQ) Phase 2 Pilot StudyCompletedNCT04800094Not applicableResults posted
• A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).CompletedNCT04729751Phase 2Results posted
• A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin DeficiencyCompletedNCT04722887Phase 1/2Results posted
• Use of Omegaven for Treatment With Parenteral Nutrition Associated Liver DiseaseCompletedNCT04697888Phase 2/3Results posted
• The BRAINFOOD Trial to Prevent Recurrent Hepatic Encephalopathy.CompletedNCT04675775Not applicableResults posted
• Ultrasound-Based Liver Fat Quantification (LFQ) Pilot StudyCompletedNCT04657523Not applicableResults posted
• STUDY OF PF-06882961 IN PARTICIPANTS WITH AND WITHOUT VARYING DEGREES OF HEPATIC IMPAIREMENTCompletedNCT04604496Phase 1Results posted
• Quantitative Ultrasound With Liver Incytes for Evaluation of Non-Alcoholic Fatty Liver DiseaseTerminatedNCT04576923Not applicableResults posted
• Velacur by Sonic Incytes for Portal HypertensionCompletedNCT04576897Not applicableResults posted
• RESTORE Declined Livers StudyCompletedNCT04483102Not applicableResults posted
• Open-Label Study to Evaluate the Safety, Tolerability, and PK of Aramchol in Subjects With Hepatic ImpairmentCompletedNCT04480827Phase 1Results posted
• A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 SubjectsCompletedNCT04480710Phase 2Results posted
• A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic ImpairmentCompletedNCT04473664Phase 1Results posted
• Michigan Alcohol Improvement Network- Alcohol Reduction and Treatment TrialCompletedNCT04473482Not applicableResults posted
• Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic SteatohepatitisCompletedNCT04399538Phase 2Results posted
• Effects of High-Intensity Interval Training Exercise in Adolescents With HepatosteatosisCompletedNCT04342390Not applicableResults posted
• Breath Analysis Based Disease BiomarkersCompletedNCT04341012Results posted
• Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)CompletedNCT04321031Phase 2Results posted
• Acamprosate Safe to Use in Individuals With Liver Disease.CompletedNCT04287920Phase 2Results posted
• Effect of Intermittent Calorie Restriction on MASLD Patients With Abnormal Glucose MetabolismCompletedNCT04283942Not applicableResults posted
• A Study of Secukinumab Treatment in Patients With Plaque Psoriasis and Coexisting Non-alcoholic Fatty Liver Disease (NAFLD)TerminatedNCT04237116Phase 3Results posted
• Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy ParticipantsCompletedNCT04223635Early Phase 1Results posted
• Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)CompletedNCT04216589Phase 2Results posted
• Vitamin E and DHA-EE on NAFLD - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD)CompletedNCT04198805Phase 2Results posted
• A STUDY TO COMPARE THE PHARMACOKINETICS OF PF-06835919 IN PARTICIPANTS WITH AND WITHOUT HEPATIC IMPAIRMENTCompletedNCT04193436Phase 1Results posted
• An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)CompletedNCT04185363Phase 3Results posted
• Effect of Probiotics in Non-alcoholic Fatty Liver Disease and SteatohepatitisTerminatedNCT04175392Phase 1/2Results posted
• MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat StudyCompletedNCT04168385Phase 2Results posted
• Study of Various Treatments in Non-alcoholic Fatty Liver Disease (NAFLD) Patients Who Have Aspects of Non-alcoholic Steatohepatitis (NASH)TerminatedNCT04147195Phase 2Results posted
• Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy SubjectsCompletedNCT04091061Phase 1Results posted
• Study of the Safety and Tolerability of AXA1125 and AXA1957 in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)CompletedNCT04073368Not applicableResults posted
• A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Severe Hepatic Impairment (HI) and Normal Hepatic FunctionCompletedNCT04056468Phase 1Results posted
• Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver FibrosisTerminatedNCT04048876Phase 2Results posted
• A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASHCompletedNCT04048135Phase 1/2Results posted
• Aspirin for the Treatment of Nonalcoholic Fatty Liver DiseaseCompletedNCT04031729Phase 1/2Results posted
• A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH.CompletedNCT04019561Phase 2Results posted
• A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of PF-06651600 in Subjects With Hepatic Impairment and Healthy VolunteersCompletedNCT04016077Phase 1Results posted
• Metabolites of Tramadol in the Postoperative Surgical PatientsCompletedNCT04004481Results posted
• A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes MellitusCompletedNCT03969719Phase 2Results posted
• Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its MetaboliteCompletedNCT03968848Phase 1Results posted
• Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)CompletedNCT03938246Phase 2Results posted
• Evaluate Severe Hepatic Impairment on Dacomitinib PKCompletedNCT03865446Phase 1Results posted
• Structured Mobile Technology Based Lifestyle Program vs Usual Care for Patients With Non-alcoholic Fatty Liver DiseaseCompletedNCT03839082Not applicableResults posted
• Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired SubjectsTerminatedNCT03818672Phase 4Results posted
• A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver ProblemsCompletedNCT03814005Phase 1Results posted
• A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.CompletedNCT03776175Phase 2Results posted
• A Culturally-Based Palliative Care Tele-consult Program for Rural Southern EldersCompletedNCT03767517Not applicableResults posted
• Hepatic Impairment Study for Lorlatinib in Cancer PatientsTerminatedNCT03726333Phase 1Results posted
• Chronic Liver Disease in Urea Cycle DisordersCompletedNCT03721367Results posted
• Evaluation of the Efficacy of Contrast Enhanced Ultrasound Compared to MRI for Differentiation of Hepatic LesionsCompletedNCT03652636Phase 4Results posted
• Safety, Tolerability, and Efficacy of Saroglitazar Mg 4 mg in Liver Transplant Recipients With Nonalcoholic Fatty Liver Disease (NAFLD)CompletedNCT03639623Phase 2Results posted
• A Hepatic Impairment Study for PF-04965842.CompletedNCT03626415Phase 1Results posted
• Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda InterferonCompletedNCT03600714Phase 2Results posted
• The SHUNT-V Study for VaricesCompletedNCT03583996Not applicableResults posted
• A Randomized Controlled Trial of an Advanced Care Planning Video Decision Support Tool for Patients With End-Stage Liver DiseaseCompletedNCT03557086Not applicableResults posted
• Tepotinib Hepatic Impairment TrialCompletedNCT03546608Phase 1Results posted
• Mild Hypothermia and Acute Kidney Injury in Liver TransplantationTerminatedNCT03534141Not applicableResults posted
• Alcohol Biosensor Monitoring for Alcoholic Liver DiseaseCompletedNCT03533660Not applicableResults posted
• NASH Fitness Intervention in Thrombosis Trial (NASHFit)CompletedNCT03518294Not applicableResults posted
• 2-Week Study In People With Nonalcoholic Fatty Liver DiseaseCompletedNCT03513588Phase 1Results posted
• Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active InfectionCompletedNCT03512210Phase 4Results posted
• A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver CirrhosisCompletedNCT03486912Phase 2Results posted
• A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver FibrosisCompletedNCT03486899Phase 2Results posted
• Losartan for the Treatment of Pediatric NAFLDTerminatedNCT03467217Phase 2Results posted
• Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver DiseaseCompletedNCT03459079Phase 2Results posted
• Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy SubjectsCompletedNCT03440424Phase 1Results posted
• Gemcabene for the Treatment of Pediatric NAFLDTerminatedNCT03436420Phase 2Results posted
• Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver DiseaseCompletedNCT03371355Phase 2Results posted
• Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment PatientsCompletedNCT03359850Phase 1Results posted
• Beyond Confounders: Addressing Source of Measurement Variability and Error in Shear Wave ElastographyCompletedNCT03342560Not applicableResults posted
• Effects of Dietary Fructose on Gut Microbiota and Fecal Metabolites in Obese Men and Postmenopausal Women: A Pilot StudyCompletedNCT03339245Not applicableResults posted
• Study of PF-05221304 in Subjects With Varying Degrees of Hepatic ImpairmentCompletedNCT03309202Phase 1Results posted
• The HepQuant SHUNT Test for Monitoring Liver Disease and Treatment Effects by Measuring Liver Function and PhysiologyTerminatedNCT03294941Phase 2Results posted
• Biomarkers of Liver Pathology in Patients With Presumed Non-Alcoholic Steatohepatitis Following Bariatric SurgeryCompletedNCT03294850Not applicableResults posted
• A Study to Evaluate the Effect of Hepatic Impairment on the Single Dose Pharmacokinetics (PK) of Intravenous TAK-954CompletedNCT03277274Phase 1Results posted
• BRIDGE Device for Post-operative Pain ControlTerminatedNCT03265249Not applicableResults posted
• 6-week Safety and PD Study in Adults With NAFLDCompletedNCT03256526Phase 2Results posted
• Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)CompletedNCT03248882Phase 2Results posted
• Benign Liver Optimal Core Study (Tissue Acquisition Comparison in Benign Liver Disease)CompletedNCT03245580Not applicableResults posted
• Normal Liver Stiffness by MR ElastographyCompletedNCT03235414Not applicableResults posted
• Daprodustat Hepatic Impairment StudyCompletedNCT03223337Phase 1Results posted
• DAA Treatment in Donor HCV-positive to Recipient HCV-negative Liver TransplantTerminatedNCT03208127Phase 4Results posted
• Monitoring of Symptoms and Cognitive Function Using TelehealthCompletedNCT03184701Not applicableResults posted
• Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASHCompletedNCT03166735Phase 2Results posted
• Role of Sildenafil for Fontan Associated Liver Disease (SiFALD) StudyCompletedNCT03154476Phase 3Results posted
• Pradaxa Tablet Proton Pump Inhibitor (PPI) Bioavailability (BA) Study in JapanCompletedNCT03143166Phase 1Results posted
• Autologous Dendritic Cell Vaccine for Treatment of Patients With Chronic HCV-InfectionCompletedNCT03119025Phase 1/2Results posted

← Liver Diseases overview